With Omonty's you are talking about a 2 BLN $ revenue stream once introduced.
Do you expect Takeda to walk away without a reintroduction!
with no baggages, Affy is in a sweet spot to get the revenues, no Sweat! Just a great Royalty revenue!
Sentiment: Strong Buy
Day dreamer.... its enough attracting commons to buy this worthless.....it will soon be over.
That is why I suspect an AMGN-TAKEDA partnership to remarket the drug. Watch for it.
That is going to be huge!